Steven Leonard Chapman Sells 5,024 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 5,024 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52. Following the sale, the chief executive officer now owns 195,686 shares in the company, valued at approximately $25,141,737.28. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The stock was sold at an average price of $118.91, for a total transaction of $663,874.53.
• On Monday, July 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The shares were sold at an average price of $102.77, for a total value of $419,712.68.
• On Monday, July 22nd, Steven Leonard Chapman sold 2,638 shares of Natera stock. The stock was sold at an average price of $105.16, for a total value of $277,412.08.
• On Monday, July 15th, Steven Leonard Chapman sold 5,496 shares of Natera stock. The shares were sold at an average price of $111.66, for a total transaction of $613,683.36.
• On Monday, July 1st, Steven Leonard Chapman sold 37,500 shares of Natera stock. The stock was sold at an average price of $108.10, for a total transaction of $4,053,750.00.

Natera Stock Up 0.5 %

Shares of NTRA stock opened at $127.78 on Friday. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $132.01. The stock has a market cap of $15.69 billion, a P/E ratio of -40.96 and a beta of 1.53. The company has a 50 day simple moving average of $114.45 and a two-hundred day simple moving average of $105.31.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The company had revenue of $413.35 million for the quarter, compared to analysts’ expectations of $343.00 million. During the same period last year, the firm earned ($0.97) EPS. Natera’s revenue for the quarter was up 58.1% compared to the same quarter last year. On average, research analysts expect that Natera, Inc. will post -1.96 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Jefferies Financial Group started coverage on shares of Natera in a report on Monday, June 3rd. They issued a “buy” rating and a $142.00 price objective for the company. TD Cowen boosted their price target on Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Canaccord Genuity Group increased their price objective on Natera from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th. Robert W. Baird lifted their price objective on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, Piper Sandler restated an “overweight” rating and set a $150.00 target price on shares of Natera in a research note on Friday, September 13th. One equities research analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $120.07.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. SG Americas Securities LLC increased its holdings in Natera by 1,073.1% in the 2nd quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock worth $7,118,000 after acquiring an additional 60,127 shares in the last quarter. Thematics Asset Management boosted its position in shares of Natera by 3.1% in the fourth quarter. Thematics Asset Management now owns 90,232 shares of the medical research company’s stock worth $5,652,000 after purchasing an additional 2,738 shares during the period. Crestline Management LP increased its stake in shares of Natera by 16.0% in the fourth quarter. Crestline Management LP now owns 65,070 shares of the medical research company’s stock worth $4,076,000 after purchasing an additional 8,997 shares in the last quarter. Russell Investments Group Ltd. raised its position in shares of Natera by 15.1% during the 1st quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock valued at $6,810,000 after purchasing an additional 9,781 shares during the period. Finally, Perceptive Advisors LLC lifted its stake in shares of Natera by 289.7% during the 4th quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock valued at $53,258,000 after buying an additional 632,047 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.